Endometrial cancer
Conditions
Interventions
Case series:Nil
Sponsors
Shanghai Institutes for Biological Sciences Chinese Academy of Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients who underwent the first uterine operation in the tumor hospital affiliated to Fudan university and had no surgical contraindication; 2. patients who sign the informed consent form and are willing to complete the study according to the plan; 3. endometrial carcinoma was confirmed pathologically in the case group after surgery, while no endometrial carcinoma was diagnosed pathologically in the control group after surgery (endometrial dysplasia and normal endometrial resection due to benign lesions); 4. aged 18-80 years old; 5. Complete clinical data (clinical diagnosis, pathological tissue staging, postoperative results, etc.) and follow-up data.
Exclusion criteria
Exclusion criteria: 1) patients who have received radiotherapy and chemotherapy before surgery; 2) patients with a history of other malignant tumors were excluded. Patients with properly treated basal or squamous cell skin cancer, cervical carcinoma in situ, or other cancers that have been disease-free for more than 5 years may be enrolled; 3) for patients with hyperglycemia that cannot be controlled by drugs, routine blood glucose >11.0mmol/L combined with clinical operation pointer does not meet the requirements for surgery; 4) for patients with abnormal thyroid function, TT3 (total serum T3), >4.5nmol/L, TT4 (total serum thyroxine), >230nmol/L, FT4 (free serum thyroxine), >FT3 (free serum T3), >17pmol/L, uTSH (hypersensitive thyrotrophin) <0.5 mm /L. 5) participate in another clinical trial within the first 30 days of randomization, and receive the investigational drugs and any concomitant treatment containing the investigational drugs; 6) immunodeficiency and AIDS patients; 7) severe heart, lung, liver and kidney insufficiency; 8) uncontrollable infection or active infection; 9) pregnant and breast-feeding women;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| endometrial cancer risk; | — |
Countries
China
Contacts
Public ContactYing Gao
Shanghai Institutes for Biological Sciences Chinese Academy of Sciences
Outcome results
None listed